Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Scientists may be step closer to developing new therapy for AML

Scientists may be step closer to developing new therapy for AML

Enrollment complete in Xencor, MorphoSys’ MOR208 phase 1 trial for CLL

Enrollment complete in Xencor, MorphoSys’ MOR208 phase 1 trial for CLL

Tuberculosis independently predicts death from lung cancer in the elderly

Tuberculosis independently predicts death from lung cancer in the elderly

Scientists map how XIAP protein activates vital component of immune defence system

Scientists map how XIAP protein activates vital component of immune defence system

Pharmacyclics announces clinical abstracts on ibrutinib to be presented at ASCO annual meeting

Pharmacyclics announces clinical abstracts on ibrutinib to be presented at ASCO annual meeting

Inovio SynCon avian influenza vaccine demonstrates broad coverage

Inovio SynCon avian influenza vaccine demonstrates broad coverage

Breast cancer cell surface protein blows cover of potent tumor-generating cells

Breast cancer cell surface protein blows cover of potent tumor-generating cells

High-throughput sequencing can detect early signs of leukemia relapse

High-throughput sequencing can detect early signs of leukemia relapse

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Ibrutinib shows promise against CLL in the elderly

Ibrutinib shows promise against CLL in the elderly

Study identifies biomarkers that can predict recurrence of prostate cancer

Study identifies biomarkers that can predict recurrence of prostate cancer

MicroRNA-3151 a new independent prognostic marker for acute leukemia

MicroRNA-3151 a new independent prognostic marker for acute leukemia

Chronic asthma sufferers may have new hope for relief due to two BWH research studies

Chronic asthma sufferers may have new hope for relief due to two BWH research studies

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Trovagene receives European patent titled, ‘Methods for Detection of Nucleic Acid Sequences in Urine’

Trovagene receives European patent titled, ‘Methods for Detection of Nucleic Acid Sequences in Urine’

Onconova advances rigosertib into new Phase II study for refractory MDS

Onconova advances rigosertib into new Phase II study for refractory MDS

Lenalidomide improves overall survival for patients with multiple myeloma

Lenalidomide improves overall survival for patients with multiple myeloma

New non-embryonic stem cell treatment for cancer and leukaemia

New non-embryonic stem cell treatment for cancer and leukaemia

Inovio first quarter total revenue decreases to $1.7 million

Inovio first quarter total revenue decreases to $1.7 million

Halozyme first quarter net loss increases to $15.1 million

Halozyme first quarter net loss increases to $15.1 million

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.